{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:43:51Z","timestamp":1782236631648,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12931-018-0769-0","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T11:51:12Z","timestamp":1524657072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases \u2013 a claims data analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Larissa","family":"Schwarzkopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Waelscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Polke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"769_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459\u2013544.","journal-title":"Lancet"},{"key":"769_CR2","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TEJ King","year":"2014","unstructured":"King TEJ, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"key":"769_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"769_CR4","doi-asserted-by":"crossref","unstructured":"Kreuter M, Cottin V. The Yin and Yang of Idiopathic Pulmonary Fibrosis. Eur Respir J. 2017;49(2).","DOI":"10.1183\/13993003.02316-2016"},{"key":"769_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1055\/s-0035-1556063","volume":"36","author":"N Putcha","year":"2015","unstructured":"Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36:575\u201391.","journal-title":"Semin Respir Crit Care Med"},{"key":"769_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1370\/afm.983","volume":"7","author":"JM Valderas","year":"2009","unstructured":"Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357\u201363.","journal-title":"Ann Fam Med"},{"key":"769_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.rmed.2014.01.008","volume":"108","author":"C Hyldgaard","year":"2014","unstructured":"Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014;108:647\u201353.","journal-title":"Respir Med"},{"key":"769_CR8","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;11:e0151425.","journal-title":"PLoS One"},{"key":"769_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/crj.12398","volume":"11","author":"A Nowinski","year":"2017","unstructured":"Nowinski A, Puscinska E, Goljan A, Peradzynska J, Bednarek M, Korzybski D, Kaminski D, Stoklosa A, Czystowska M, Sliwinski P, Gorecka D. The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study. Clin Respir J. 2017;11:648\u201356.","journal-title":"Clin Respir J"},{"key":"769_CR10","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Lokke A, Bendstrup E, Ellingsen T. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700\u20136.","journal-title":"Ann Rheum Dis"},{"key":"769_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1378\/chest.06-3087","volume":"132","author":"NM Patel","year":"2007","unstructured":"Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007;132:998\u20131006.","journal-title":"Chest"},{"key":"769_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","volume":"147","author":"S Tomassetti","year":"2015","unstructured":"Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157\u201364.","journal-title":"Chest"},{"key":"769_CR13","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.rmed.2010.02.008","volume":"104","author":"SD Nathan","year":"2010","unstructured":"Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, Burton N, Barnett SD. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010;104:1035\u201341.","journal-title":"Respir Med"},{"key":"769_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1378\/chest.08-2776","volume":"136","author":"LH Lancaster","year":"2009","unstructured":"Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136:772\u20138.","journal-title":"Chest"},{"key":"769_CR15","doi-asserted-by":"crossref","unstructured":"Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in Interstitial Lung Diseases. Eur Respir Rev. 2017;26(143).","DOI":"10.1183\/16000617.0027-2016"},{"key":"769_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","volume":"46","author":"G Raghu","year":"2015","unstructured":"Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113\u201330.","journal-title":"Eur Respir J"},{"key":"769_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.rmed.2017.06.001","volume":"129","author":"I Buendia-Roldan","year":"2017","unstructured":"Buendia-Roldan I, Mejia M, Navarro C, Selman M. Idiopathic pulmonary fibrosis: clinical behavior and aging associated comorbidities. Respir Med. 2017;129:46\u201352.","journal-title":"Respir Med"},{"key":"769_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MCP.0b013e328363f460","volume":"19","author":"C King","year":"2013","unstructured":"King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013;19:466\u201373.","journal-title":"Curr Opin Pulm Med"},{"key":"769_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","volume":"4","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4:381\u20139.","journal-title":"Lancet Respir Med"},{"key":"769_CR20","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1183\/13993003.02087-2015","volume":"47","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47:1776\u201384.","journal-title":"Eur Respir J"},{"key":"769_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/thoraxjnl-2016-208819","volume":"72","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax. 2017;72:148\u201353.","journal-title":"Thorax"},{"key":"769_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00103-012-1626-9","volume":"56","author":"J Jaunzeme","year":"2013","unstructured":"Jaunzeme J, Eberhard S, Geyer S. Wie \u201crepr\u00e4sentativ\u201d sind GKV-Daten? Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56:447\u201354.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"769_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0035-1562981","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, Ihle P. Gute Praxis Sekund\u00e4rdatenanalyse (GPS): Leitlinien und Empfehlungen. Gesundheitswesen. 2015;77:120\u20136.","journal-title":"Gesundheitswesen"},{"key":"769_CR24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1164\/rccm.201504-0818OC","volume":"192","author":"DB Esposito","year":"2015","unstructured":"Esposito DB, Lanes S, Donneyong M, Holick CN, Lasky JA, Lederer D, Nathan SD, O'Quinn S, Parker J, Tran TN. Idiopathic pulmonary fibrosis in United States automated claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med. 2015;192:1200\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"769_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","volume":"4","author":"SL Walsh","year":"2016","unstructured":"Walsh SL, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, Nunes H, Valeyre D, Brillet PY, Kambouchner M, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;4:557\u201365.","journal-title":"Lancet Respir Med"},{"key":"769_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8\u201327.","journal-title":"Med Care"},{"key":"769_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"769_CR28","first-page":"309","volume":"8","author":"BG Fulton","year":"2015","unstructured":"Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med. 2015;8:309\u201318.","journal-title":"Int J Gen Med"},{"key":"769_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34:187\u2013220.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"769_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","volume":"186","author":"M Divo","year":"2012","unstructured":"Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"769_CR31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc. 1996;58:267\u201388.","journal-title":"J R Stat Soc"},{"key":"769_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the cox model. Stat Med. 1997;16:385\u201395.","journal-title":"Stat Med"},{"key":"769_CR33","first-page":"72","volume":"2015","author":"G Oyeyemi","year":"2015","unstructured":"Oyeyemi G, Oluwole Ogunjobi E, Idowu Folorunsho A. On performance of shrinkage methods \u2013 a Monte Carlo study. Int J Stat Appl. 2015;2015:72\u20136.","journal-title":"Int J Stat Appl"},{"key":"769_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1214\/13-AOS1175","volume":"42","author":"R Lockhart","year":"2014","unstructured":"Lockhart R, Taylor J, Tibshirani RJ, Tibshirani R. A significance test for the lasso. Ann Stat. 2014;42:413\u201368.","journal-title":"Ann Stat"},{"key":"769_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.01.013","volume":"67","author":"JF Piccirillo","year":"2008","unstructured":"Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67:124\u201332.","journal-title":"Crit Rev Oncol Hematol"},{"key":"769_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"769_CR37","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00103-012-1504-5","volume":"55","author":"B-M Kurth","year":"2012","unstructured":"Kurth B-M. Erste Ergebnisse aus der - Studie zur Gesundheit Erwachsener in Deutschland? (DEGS). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2012;55:980\u201390.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"769_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2213-2600(16)30222-3","volume":"5","author":"CS King","year":"2017","unstructured":"King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5:72\u201384.","journal-title":"Lancet Respir Med"},{"issue":"37","key":"769_CR39","first-page":"67","volume":"2016","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;2016(37):67\u2013119.","journal-title":"Eur Heart J"},{"key":"769_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11325-014-1033-6","volume":"19","author":"C Mermigkis","year":"2015","unstructured":"Mermigkis C, Bouloukaki I, Antoniou K, Papadogiannis G, Giannarakis I, Varouchakis G, Siafakas N, Schiza SE. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath. 2015;19:385\u201391.","journal-title":"Sleep Breath"},{"key":"769_CR41","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","volume":"184","author":"JS Lee","year":"2011","unstructured":"Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:1390\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"769_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S2213-2600(17)30219-9","volume":"5","author":"KA Johannson","year":"2017","unstructured":"Johannson KA, Strambu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? Lancet Respir Med. 2017;5:591\u20138.","journal-title":"Lancet Respir Med"},{"key":"769_CR43","first-page":"121","volume":"30","author":"S Tomassetti","year":"2013","unstructured":"Tomassetti S, Ruy JH, Gurioli C, Ravaglia C, Buccioli M, Tantalocco P, Decker PA, Cavazza A, Dubini A, Agnoletti V, et al. The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:121\u20137.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"769_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","volume":"186","author":"I Noth","year":"2012","unstructured":"Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"769_CR45","doi-asserted-by":"publisher","first-page":"e0140571","DOI":"10.1371\/journal.pone.0140571","volume":"10","author":"S Vedel-Krogh","year":"2015","unstructured":"Vedel-Krogh S, Nielsen SF, Nordestgaard BG. Statin use is associated with reduced mortality in patients with interstitial lung disease. PLoS One. 2015;10:e0140571.","journal-title":"PLoS One"},{"key":"769_CR46","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00103-008-0644-0","volume":"51","author":"I Schubert","year":"2008","unstructured":"Schubert I, K\u00f6ster I, K\u00fcpper-Nybelen J, Ihle P. Versorgungsforschung mit GKV-Routinedaten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2008;51:1095\u2013105.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"769_CR47","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/j.1475-6773.2005.00444.x","volume":"40","author":"KJ O'Malley","year":"2005","unstructured":"O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40:1620\u201339.","journal-title":"Health Serv Res"},{"key":"769_CR48","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"769_CR49","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","volume":"69","author":"NS Goh","year":"2017","unstructured":"Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69:1670\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"769_CR50","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/JTO.0000000000000209","volume":"9","author":"N Girard","year":"2014","unstructured":"Girard N, Marchand-Adam S, Naccache JM, Borie R, Urban T, Jouneau S, Marchand E, Ravel AC, Kiakouama L, Etienne-Mastroianni B, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 western patients. J Thorac Oncol. 2014;9:1162\u201370.","journal-title":"J Thorac Oncol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-018-0769-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T08:45:45Z","timestamp":1720255545000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-018-0769-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1186\/s12931-018-0769-0","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]},"assertion":[{"value":"27 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We performed a retrospective analysis of completely anonymized data. According to the German Guidelines for Secondary Data Analysis, ethical approval and consent to participate is not required for this type of study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have fully acknowledged any competing financial or personal interests with regard to this research project. LS, SW, and MP do not have any conflicting interests related directly or indirectly to the project. JW reports personal fees from Boehringer Ingelheim and Roche outside the submitted work. MK acknowledges grants and personal fees from Boehringer Ingelheim and Roche outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"73"}}